A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea
A Vehicle-Controlled, Double-Blind, Randomized Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Rosacea
Sponsor: AOBiome LLC
Listed as NCT03590366, this PHASE2 trial focuses on Rosacea and remains completed. Sponsored by AOBiome LLC, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Sep 2019 — Aug 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Jan 2019 [monthly]
Recruiting PHASE2
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AOBiome LLC
- bioRASI, LLC
For direct contact, visit the study record on ClinicalTrials.gov .